Gary E. Pakes

2.6k total citations
49 papers, 2.0k citations indexed

About

Gary E. Pakes is a scholar working on Infectious Diseases, Virology and Pharmacology. According to data from OpenAlex, Gary E. Pakes has authored 49 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 17 papers in Virology and 8 papers in Pharmacology. Recurrent topics in Gary E. Pakes's work include HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (17 papers) and HIV/AIDS Research and Interventions (12 papers). Gary E. Pakes is often cited by papers focused on HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (17 papers) and HIV/AIDS Research and Interventions (12 papers). Gary E. Pakes collaborates with scholars based in United States, United Kingdom and Netherlands. Gary E. Pakes's co-authors include G.S. Avery, T.M. Speight, Rex N. Brogden, R.C. Heel, Geoffrey J. Yuen, Katy H. P. Moore, Mark Johnson, Alan Bye, Steve Weller and Keith A. Pappa and has published in prestigious journals such as JAMA, Antimicrobial Agents and Chemotherapy and Journal of Pharmaceutical Sciences.

In The Last Decade

Gary E. Pakes

49 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary E. Pakes United States	21	784	413	300	241	236	49	2.0k
Christopher J. Destache United States	31	927 1.2×	703 1.7×	535 1.8×	212 0.9×	316 1.3×	128	3.2k
Qing Ma United States	29	709 0.9×	508 1.2×	332 1.1×	361 1.5×	134 0.6×	164	2.8k
Yechiel A. Hekster Netherlands	29	753 1.0×	481 1.2×	257 0.9×	155 0.6×	279 1.2×	73	2.7k
J. Heykants Belgium	22	650 0.8×	500 1.2×	227 0.8×	64 0.3×	263 1.1×	59	2.2k
Y. A. Hekster Netherlands	27	621 0.8×	330 0.8×	320 1.1×	132 0.5×	538 2.3×	116	2.3k
Joseph E. Rower United States	19	797 1.0×	342 0.8×	341 1.1×	89 0.4×	129 0.5×	58	1.3k
Alain Pruvost France	30	885 1.1×	542 1.3×	323 1.1×	150 0.6×	132 0.6×	80	2.2k
D.J. Back United Kingdom	29	596 0.8×	347 0.8×	172 0.6×	125 0.5×	197 0.8×	80	2.2k
John Ruedy Canada	22	524 0.7×	402 1.0×	307 1.0×	71 0.3×	158 0.7×	55	1.5k
Kenneth C. Cundy United States	27	839 1.1×	484 1.2×	839 2.8×	82 0.3×	126 0.5×	54	3.0k

Countries citing papers authored by Gary E. Pakes

Since Specialization

Citations

This map shows the geographic impact of Gary E. Pakes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary E. Pakes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary E. Pakes more than expected).

Fields of papers citing papers by Gary E. Pakes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary E. Pakes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary E. Pakes. The network helps show where Gary E. Pakes may publish in the future.

Co-authorship network of co-authors of Gary E. Pakes

This figure shows the co-authorship network connecting the top 25 collaborators of Gary E. Pakes. A scholar is included among the top collaborators of Gary E. Pakes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary E. Pakes. Gary E. Pakes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Squires, Kathleen, Benjamin Young, Lizette Santiago, et al.. (2017). Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. HIV/AIDS - Research and Palliative Care. Volume 9. 51–61. 5 indexed citations

Cespedes, Michelle, Delivette Castor, Susan L. Ford, et al.. (2013). Steady-State Pharmacokinetics, Cord Blood Concentrations, and Safety of Ritonavir-Boosted Fosamprenavir in Pregnancy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(5). 550–554. 12 indexed citations

Young, Benjamin, Kathleen Squires, Lisa Ross, et al.. (2012). Inflammatory Biomarker Changes and Their Correlation with Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-Naive HIV-Infected Patients Treated for 144 Weeks with Abacavir/Lamivudine/Atazanavir with or without Ritonavir in ARIES. AIDS Research and Human Retroviruses. 29(2). 350–358. 17 indexed citations

Garner, R. Colin, Lawrence Lee, Mark Seymour, et al.. (2010). Accelerator Mass Spectrometry Measurement of Intracellular Concentrations of Active Drug Metabolites in Human Target Cells In Vivo. Clinical Pharmacology & Therapeutics. 88(6). 796–800. 7 indexed citations

Ross, Lisa, Winkler G. Weinberg, Edwin DeJesus, et al.. (2010). Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected Patients. AIDS Research and Human Retroviruses. 26(4). 407–417. 8 indexed citations

Hicks, Charles B., Edwin DeJesus, Louis Sloan, et al.. (2009). Comparison of Once-Daily Fosamprenavir Boosted with Either 100 or 200 mg of Ritonavir, in Combination with Abacavir/Lamivudine: 96-Week Results from COL100758. AIDS Research and Human Retroviruses. 25(4). 395–403. 17 indexed citations

Pakes, Gary E., et al.. (2009). Steady-State Amprenavir, Tenofovir, and Emtricitabine Pharmacokinetics Before and After Reducing Ritonavir Boosting of a Fosamprenavir/Tenofovir/Emtricitabine Regimen from 200 mg to 100 mg Once Daily (TELEX II). HIV Clinical Trials. 10(3). 160–167. 7 indexed citations

Collier, Ann C., Camlin Tierney, Gerald Downey, et al.. (2008). Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV. HIV Clinical Trials. 9(2). 91–102. 8 indexed citations

Yuen, Geoffrey J., Steve Weller, & Gary E. Pakes. (2008). A Review of the Pharmacokinetics of Abacavir. Clinical Pharmacokinetics. 47(6). 351–371. 110 indexed citations

10.

Smith, Kimberly Y., Winkler G. Weinberg, Edwin DeJesus, et al.. (2008). Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Research and Therapy. 5(1). 5–5. 79 indexed citations

11.

Shoemaker, Ritchie C., et al.. (2006). Atovaquone plus cholestyramine in patients coinfected withBabesia microti andBorrelia burgdorferi refractory to other treatment. Advances in Therapy. 23(1). 1–11. 9 indexed citations

12.

Kumar, Princy, Melanie Thompson, Karen T. Tashima, et al.. (2006). A prospective, 96‐week study of the impact of Trizivir^®, Combivir^®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity. HIV Medicine. 7(2). 85–98. 60 indexed citations

13.

Keiser, Philip, Michael Sension, Edwin DeJesus, et al.. (2005). Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infectious Diseases. 5(1). 2–2. 31 indexed citations

14.

Moore, Katy H. P., et al.. (1999). Lamivudine/Zidovudine as a Combined Formulation Tablet: Bioequivalence Compared with Lamivudine and Zidovudine Administered Concurrently and the Effect of Food on Absorption. The Journal of Clinical Pharmacology. 39(6). 593–605. 41 indexed citations

15.

Moore, Katy H. P., et al.. (1999). The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 13(16). 2239–2250. 115 indexed citations

16.

Moore, Katy H. P., Geoffrey J. Yuen, Elizabeth K. Hussey, et al.. (1999). Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials. Antimicrobial Agents and Chemotherapy. 43(12). 3025–3029. 36 indexed citations

17.

Johnson, Mark, Katy H. P. Moore, Geoffrey J. Yuen, Alan Bye, & Gary E. Pakes. (1999). Clinical Pharmacokinetics of Lamivudine. Clinical Pharmacokinetics. 36(1). 41–66. 223 indexed citations

18.

Bozigian, Haig, et al.. (1994). Ondansetron Absorption in Adults: Effect of Dosage Form, Food, and Antacids. Journal of Pharmaceutical Sciences. 83(7). 1011–1013. 25 indexed citations

19.

Pakes, Gary E.. (1994). Cefuroxime axetil in the treatment of sinusitis. A review. Archives of Family Medicine. 3(2). 165–175. 8 indexed citations

20.

Hussey, Elizabeth K., et al.. (1991). Albuterol Extended‐Release Products: Effect of Food on the Pharmacokinetics of Single Oral Doses of Volmax® and Proventil® Repetabs® in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 31(6). 561–564. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact